Tallac Therapeutics
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors (NCT05399654) | Tallac Therapeutics | 2022-06-28 |
Track Tallac Therapeutics automatically
Every clearance here is in the API, with alerts when new ones post.